130 related articles for article (PubMed ID: 33086481)
1. Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center Analysis.
Karin M; Taugner J; Käsmann L; Eze C; Roengvoraphoj O; Tufman A; Belka C; Manapov F
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33086481
[TBL] [Abstract][Full Text] [Related]
2. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
[TBL] [Abstract][Full Text] [Related]
3. Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting.
Taugner J; Käsmann L; Eze C; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33807324
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis.
Flörsch B; Taugner J; Käsmann L; Kenndoff S; Guggenberger J; Tufman A; Reinmuth N; Duell T; Belka C; Eze C; Manapov F
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3267-3276. PubMed ID: 35915184
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
6. Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
Käsmann L; Eze C; Taugner J; Nieto A; Hofstetter K; Kröninger S; Guggenberger J; Kenndoff S; Flörsch B; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7393-7403. PubMed ID: 36939927
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and efficacy of helical intensity-modulated radiotherapy for stage III non-small cell lung cancer in comparison with conventionally fractionated 3D-CRT.
He J; Huang Y; Chen Y; Shi S; Ye L; Hu Y; Zhang J; Zeng Z
J Thorac Dis; 2016 May; 8(5):862-71. PubMed ID: 27162660
[TBL] [Abstract][Full Text] [Related]
8. Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer.
Wiersma TG; Dahele M; Verbakel WF; van de Ven PM; de Haan PF; Smit EF; van Reij EJ; Slotman BJ; Senan S
Lung Cancer; 2013 Apr; 80(1):62-7. PubMed ID: 23357464
[TBL] [Abstract][Full Text] [Related]
9. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
[TBL] [Abstract][Full Text] [Related]
10. Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy.
Hoffmann M; Reitz D; Taugner J; Roengvoraphoj O; Käsmann L; Eze C; Karin M; Belka C; Manapov F
Anticancer Res; 2020 Apr; 40(4):2319-2322. PubMed ID: 32234932
[TBL] [Abstract][Full Text] [Related]
11. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902
[TBL] [Abstract][Full Text] [Related]
12. Association of Target Volume Margins With Locoregional Control and Acute Toxicities for Non-small cell lung cancer Treated With Concurrent Chemoradiation Therapy.
Yegya-Raman N; Reyhan M; Kim S; Deek MP; Yue N; Zou W; Malhotra J; Aisner J; Jabbour SK
Pract Radiat Oncol; 2019 Jan; 9(1):e74-e82. PubMed ID: 30144583
[TBL] [Abstract][Full Text] [Related]
13. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma.
Bradley JD; Ieumwananonthachai N; Purdy JA; Wasserman TH; Lockett MA; Graham MV; Perez CA
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):49-57. PubMed ID: 11777621
[TBL] [Abstract][Full Text] [Related]
14. Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy.
Taugner J; Käsmann L; Eze C; Dantes M; Roengvoraphoj O; Gennen K; Karin M; Petruknov O; Tufman A; Belka C; Manapov F
Transl Lung Cancer Res; 2019 Oct; 8(5):593-604. PubMed ID: 31737496
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
[TBL] [Abstract][Full Text] [Related]
16. Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer.
Karam SD; Horne ZD; Hong RL; Baig N; Gagnon GJ; McRae D; Duhamel D; Nasr NM
Lung Cancer (Auckl); 2013; 4():35-42. PubMed ID: 28210133
[TBL] [Abstract][Full Text] [Related]
17. Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?
Ma JT; Sun L; Sun X; Xiong ZC; Liu Y; Zhang SL; Huang LT; Han CB
Radiat Oncol; 2017 Feb; 12(1):34. PubMed ID: 28143532
[TBL] [Abstract][Full Text] [Related]
18. Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database.
Brower JV; Amini A; Chen S; Hullett CR; Kimple RJ; Wojcieszynski AP; Bassetti M; Witek ME; Yu M; Harari PM; Baschnagel AM
Ann Oncol; 2016 Oct; 27(10):1887-94. PubMed ID: 27502703
[TBL] [Abstract][Full Text] [Related]
19. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.
Flentje M; Huber RM; Engel-Riedel W; Andreas S; Kollmeier J; Staar S; Dickgreber N; Vaissiere N; De Almeida C; Edlich B; Fietkau R
Strahlenther Onkol; 2016 Apr; 192(4):216-22. PubMed ID: 26809652
[TBL] [Abstract][Full Text] [Related]
20. SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status.
Maguire J; Khan I; McMenemin R; O'Rourke N; McNee S; Kelly V; Peedell C; Snee M
Eur J Cancer; 2014 Nov; 50(17):2939-49. PubMed ID: 25304298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
